257 related articles for article (PubMed ID: 25585100)
21. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
22. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
23. Cytokine modified tumor vaccines.
Armstrong TD; Jaffee EM
Surg Oncol Clin N Am; 2002 Jul; 11(3):681-96. PubMed ID: 12487062
[TBL] [Abstract][Full Text] [Related]
24. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
Koido S; Okamoto M; Shimodaira S; Sugiyama H
Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
[TBL] [Abstract][Full Text] [Related]
25. T cell optimization for the treatment of pancreatic cancer.
Liu F; Saif MW
Expert Opin Biol Ther; 2017 Dec; 17(12):1493-1501. PubMed ID: 28835191
[TBL] [Abstract][Full Text] [Related]
26. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
27. Prospects for vaccine therapy for pancreatic cancer.
Gaudernack G
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):299-314. PubMed ID: 16549329
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
30. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
Cheng X; Zhao G; Zhao Y
Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
[TBL] [Abstract][Full Text] [Related]
31. Vaccines for pancreatic cancer.
Soares KC; Zheng L; Edil B; Jaffee EM
Cancer J; 2012; 18(6):642-52. PubMed ID: 23187853
[TBL] [Abstract][Full Text] [Related]
32. Current immunotherapeutic strategies in pancreatic cancer.
Plate JM
Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552
[TBL] [Abstract][Full Text] [Related]
33. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities.
Yu Z; Ren P; Zhang X; Zhang T; Ma B
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1065-71. PubMed ID: 19671026
[TBL] [Abstract][Full Text] [Related]
35. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
37. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
Mizuguchi T; Torigoe T; Satomi F; Shima H; Kutomi G; Ota S; Ishii M; Hayashi H; Asakura S; Hirohashi Y; Meguro M; Kimura Y; Nishidate T; Okita K; Ishino M; Miyamoto A; Hatakenaka M; Sato N; Hirata K
Surg Today; 2016 Feb; 46(2):139-48. PubMed ID: 25649538
[TBL] [Abstract][Full Text] [Related]
38. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
Kubo T; Tsurita G; Hirohashi Y; Yasui H; Ota Y; Watanabe K; Murai A; Matsuo K; Asanuma H; Shima H; Wada S; Nakatsugawa M; Kanaseki T; Tsukahara T; Mizuguchi T; Hirata K; Takemasa I; Imai K; Sato N; Torigoe T
Cancer Sci; 2019 Aug; 110(8):2386-2395. PubMed ID: 31206934
[TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
McCormick KA; Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Hum Vaccin Immunother; 2016 Mar; 12(3):563-75. PubMed ID: 26619245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]